Real world study of safety and efficacy of lorlatinib as second line and beyond in < em > ALK < /em > -rearranged advanced non-small cell lung cancer patients in India - a multicentre chart review study (ROSELAND)

CONCLUSION: Lorlatinib was highly efficacious in terms of overall response rate, median PFS and median OS in this small real-world cohort of advanced ALK+ve NSCLC with a manageable safety profile.PMID:38439810 | PMC:PMC10911676 | DOI:10.3332/ecancer.2024.1667

Source: Ecancermedicalscience - March 5, 2024 Category: Cancer & Oncology Authors: Bivas Biswas Nikhil S Ghadyalpatil Shekar Patil Amol Patel Sandip Ganguly Anvesh Rathore Bhupesh Guleria Cpalli Firdouse Tarannum Joydeep Ghosh Mary Sravani Kondapally Ravi Thippeswamy Shashidhara Haragadde Poppa Reddy Somnath Roy Source Type: research